|
|
Temozolomide
as a second-line systemic regimen in recurrent high-grade glioma: a phase II
study
Brandes AA, Ermani M, Basso U, Amista P, Berti F, Scienza R, Rotilio
A, Pinna G, Gardiman M, Monfardini S.
Department of
Medical Oncology, Azienda Ospedaliera, Padova, Italy. brandes@ux1.unipd.it
Background. To investigate the efficacy of temozolomide in relation to response
rate, toxicity, time to progression. and median survival time, a phase II study
was conducted in patients with recurrent high-grade glioma following surgery
plus radiotherapy and first-line chemotherapy based on nitrosourea, procarbazine
and vincristine.
Patients and Methods. Forty-one patients with high-grade glioma, at second
recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme,
ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma
were administered temozolomide, 150 mg/m2/daily for five days every four weeks.
Results. Response was assessed in 40 patients.
The overall response rate (complete + partial response) was 22.5% (95%
confidence interval (CI): 9.5%-35%).
The median time to progression for all 41 patients was 22.3 weeks;
progression-free survival at 6 and 12 months was 48.5% and 34.7%, respectively.
Median survival time was 37.1 weeks with 80.2% at 6 and 34.9% survival at 12
months.
Conclusions. On multivariate analysis, response to previous treatment was
significant (P = 0.03) for time to progression and Karnofsky performance score
for overall survivall (P = 0.002).
Temozolomide gave a moderate response rate with acceptable toxicity as
second-line chemotherapy in patients with recurrent high-grade glioma.
PMID: 11300334 [PubMed - indexed for
MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11300334&dopt=Abstract
|
